Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

rter of 2008 represented a net after-tax expense of euro 148 million.

In the first half of 2009, selected items represented a net after-tax expense of euro 608 million compared with a net after-tax expense of euro 168 million for the first half of 2008, and comprised:

  • euro 907 million of restructuring costs arising from the Group's adaptation program;
  • euro 20 million of impairment losses arising from the decision to discontinue development of TroVax((R));
  • the euro 319 million tax effect arising on the selected items described above.

Adjustments in the consolidated financial statements to reflect the application of purchase accounting to acquisitions, primarily that of Aventis

The material effects of the application of purchase accounting to acquisitions, primarily that of Aventis, on the consolidated income statement were as follows:

  • A charge of euro 19 million in the second quarter arising from the workdown of inventories of Zentiva and other companies acquired during the period remeasured at fair value.
  • An amortization charge of euro 1,708 million against intangible assets, of which euro 864 million was booked in the second quarter.
  • An impairment loss of euro 8 million charged against the Di-Antalvic asset in the second quarter.
  • Deferred taxes of euro 577 million, of which euro 293 million was booked in the second quarter. These deferred taxes were generated by the amortization charged against intangible assets, the workdown of inventories of acquired companies, and the impairment loss charged against the Di-Antalvic asset.
  • In "Share of profits/losses of associates", a reversal of euro 43 million, of which euro 21 million was booked in the second quarter, relating to the amortization of intangible assets (net of tax).
    • '/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...
(Date:6/18/2013)... , June 18, 2013 ... investment research firm, announces the initiation of ... French biopharmaceutical company developing and marketing products ... indications.      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... report examining the investment merits of BioAlliance ...
(Date:6/18/2013)... June 18, 2013 Mapi Pharma Ltd. ... and innovative intermediates, and finished dosage forms based on selected ... granted a United States patent for ... Europe for the oral treatment of moderate-to-severe acute ... Intermediate Compounds and Processes for the Preparation of Tapentadol ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing ) has announced the addition of ... Markets and Companies " to their offering. ... This report briefly reviews basics of human ... their applications. Current large and small sequencers ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... Conference Call at 12:30 p.m. Eastern Time, September 19, ... ... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that Allergan, Inc.,(NYSE: ... States rights to SANCTURA(R) and SANCTURA(R) XR. In connection with,Allergan,s acquisition of ...
... announced that it has filed a registration statement on Form,S-1 ... proposed,initial public offering of its common stock. All of ... The,number of shares to be offered and the price range ... to apply to have its common stock,approved for quotation on ...
... 19 ,Arpida Ltd (SWX: ARPN) was invited to ... new antimicrobial agents at the 47th annual,Interscience Conference ... is a major scientific conference where thousands of,scientists ... to discuss the,latest developments in the field of ...
Cached Biology Technology:Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:6/18/2013)... has awarded $12.7 million to match nine academic ... compounds to explore new treatments for patients in ... dystrophy and schizophrenia. The collaborative pilot initiative, called ... led by the National Center for Advancing Translational ... Fund. , The process of developing a new ...
(Date:6/18/2013)... of breast and ovarian cancers are familial in origin, ... to inherited mutations from the parents in genes such ... PARP inhibitors, which are currently in clinical trials, have ... for personalised cancer treatment, an alternative to standard chemotherapy. ... these patients generate resistance to the drug and, therefore, ...
(Date:6/17/2013)... in the U.S. exposed to high levels of air pollution ... a child with autism as women who lived in areas ... School of Public Health (HSPH). It is the first large ... across the U.S. , "Our findings raise concerns since, depending ... our study lived in areas where risk of autism was ...
Breaking Biology News(10 mins):NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... 15, 2011 BGI, the world,s largest genomics organization, ... Oregon State University to conduct collaborative de novo genome ... plant pathogens. This agreement kicks off a larger ... Genus Sequencing Consortium, to conduct collaborative de novo genome ...
... even in the cloudiest conditions, while the lush interiors ... canopy. The ability of trees to adapt to light ... photosynthesis in poor light, has been explored by Czech ... Functional Ecology . The research centers around the ...
... In a review study, researchers from Tufts University ... use of antibiotics in food animals and fish farming ... the preponderance of evidence argues for stricter regulation of ... resistance, notes that a guiding tenet of public health, ...
Cached Biology News:BGI announces collaborative research agreements with Oregon State University 2Trees adapt to poor levels of sunlight to effectively process carbon, study shows 2Evidence supports ban on growth promotion use of antibiotics in farming 2Evidence supports ban on growth promotion use of antibiotics in farming 3Evidence supports ban on growth promotion use of antibiotics in farming 4
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
IHC detection kit for BrdU in cells and tissues...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Biology Products: